Ovid Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ovid Therapeutics Inc 's ROA in the second quarter of 2026?
Ovid Therapeutics Inc recorded a cumulative net loss of $-34 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -20.52%.

However, within the Healthcare sector 363 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3426, from total ROA ranking in the first quarter of 2026 at 4018.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	199.6 %	176.32 %	145.93 %	-29.42 %	-27.34 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-34	-24	-17	-36	-38
Return On Assets (TTM)	-20.52 %	-18.67 %	-18.63 %	-51.12 %	-49.12 %
OVID's Total Ranking	# 3426	# 4018	# 3986	# 3995	# 3748
Total Assets (TTM) in million	232	226	151	64	77
Seq. Total Assets Change	2.81 %	49.49 %	136.4 %	-17.54 %	-5.18 %
Seq. Net Income Change	-	-	-	-	-

OVID's 5 Years Annual ROA >> Back to OVID Management Effectiveness >> Compare OVID ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 132
Sector	# 364
Overall	# 3432

Return On Assets Statistics
High	Average	Low
102.15 %	-41.24 %	-133.3 %
(Mar 31 2021)		(Jun 30 2020)

Financial Statements
Ovid Therapeutics Inc 's Assets	$ 232 million	OVID's Balance sheet
Ovid Therapeutics Inc 's Income	$ -15 million	Quarterly OVID's Income Statement
OVID's Income by Division		See OVID's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	219.57 %	108.56 %	-38.08 %	-6.44 %	-26.93 %
Total Assets in million	549	172	82	133	142
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-17	-26	-52	-54	120
Annual Return On Assets	-3.17 %	-15.39 %	-63.56 %	-40.73 %	84.3 %

OVID's 5 Years Annual ROA >> Back to OVID Management Effectiveness >> Compare OVID ROA to its Competitors

More Return On Assets Ratios
OVID's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OVID's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OVID's Competitors
Subscribers only: Roa for Ovid Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for OVID's Customers

You may also want to know
OVID's Roi	OVID's Inventory Turnover Ratio	OVID's Growth Rates	OVID's Dividend Comparisons
	OVID's Profitability Ratios	OVID's Asset Turnover Ratio	OVID's Dividend Growth
OVID's Roe	OVID's Valuation Ratios	OVID's Financial Strength Ratios	OVID's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T20:57:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.